
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
KALA | NASDAQ | USD | Real-time | |
0JQ2 | London | USD | Real-time | |
27F0 | Frankfurt | EUR | Delayed |
KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company’s lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Andrew I. Koven | 66 | 2017 | Lead Independent Director |
Howard B. Rosen | 65 | 2014 | Independent Director & Member of Advisory Board |
Bennett M. Shapiro | 84 | - | Member of Scientific Advisory Board |
Jonathan Todd Silverstein | 57 | 2016 | Board Observer |
Ronald Lee Krall | - | - | Member of Scientific Advisory Board |
Colin R. Gardner | - | - | Member of Scientific Advisory Board |
Marjan Farid | 50 | 2022 | Independent Director |
Gregory D. Perry | 64 | 2018 | Independent Director |
Charles Daniel Myers | 70 | 2021 | Independent Director |
Justin Hanes | - | - | Founder & Chair of the Scientific Advisory Board |
Mark T. Iwicki | 59 | 2015 | Chairman |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review